Elanco Animal Health Incorporated (NYSE:ELAN) Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets grew its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 2,453.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 260,325 shares of the company's stock after purchasing an additional 250,129 shares during the period. BNP Paribas Financial Markets owned approximately 0.05% of Elanco Animal Health worth $3,824,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Commerce Bank boosted its holdings in Elanco Animal Health by 2.2% in the 3rd quarter. Commerce Bank now owns 35,114 shares of the company's stock valued at $516,000 after purchasing an additional 741 shares in the last quarter. 180 Wealth Advisors LLC raised its position in Elanco Animal Health by 3.6% in the second quarter. 180 Wealth Advisors LLC now owns 25,716 shares of the company's stock worth $352,000 after acquiring an additional 893 shares in the last quarter. HBK Sorce Advisory LLC lifted its holdings in Elanco Animal Health by 9.4% in the second quarter. HBK Sorce Advisory LLC now owns 12,920 shares of the company's stock valued at $186,000 after acquiring an additional 1,107 shares during the period. Atomi Financial Group Inc. boosted its position in shares of Elanco Animal Health by 11.1% during the 2nd quarter. Atomi Financial Group Inc. now owns 12,260 shares of the company's stock worth $177,000 after purchasing an additional 1,221 shares in the last quarter. Finally, Keene & Associates Inc. boosted its holdings in Elanco Animal Health by 5.7% during the third quarter. Keene & Associates Inc. now owns 22,945 shares of the company's stock worth $337,000 after buying an additional 1,240 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Analysts Set New Price Targets

ELAN has been the topic of a number of research reports. Stifel Nicolaus reissued a "buy" rating and issued a $20.00 price objective on shares of Elanco Animal Health in a research note on Thursday, September 19th. Morgan Stanley cut shares of Elanco Animal Health from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $17.00 to $15.00 in a research note on Thursday, September 19th. Leerink Partnrs upgraded Elanco Animal Health to a "hold" rating in a report on Monday. Barclays increased their price target on Elanco Animal Health from $19.00 to $20.00 and gave the stock an "overweight" rating in a research note on Friday, November 8th. Finally, Leerink Partners began coverage on Elanco Animal Health in a research report on Monday. They issued a "market perform" rating and a $14.00 price objective for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $16.75.

Elanco Animal Health Trading Down 1.2 %

Shares of NYSE:ELAN traded down $0.15 during trading on Thursday, reaching $12.10. 6,368,993 shares of the stock were exchanged, compared to its average volume of 4,773,366. Elanco Animal Health Incorporated has a 12-month low of $11.40 and a 12-month high of $18.80. The firm's 50-day moving average price is $13.49 and its 200 day moving average price is $14.54. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The firm has a market cap of $5.98 billion, a price-to-earnings ratio of 30.63, a price-to-earnings-growth ratio of 2.02 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the previous year, the firm earned $0.18 earnings per share. Elanco Animal Health's revenue for the quarter was down 3.6% on a year-over-year basis. On average, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.92 earnings per share for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.